Eltrombopag


- TRADE NAMES: Promacta (Novartis); Revolade (Novartis)
- INDICATIONS: Thrombocytopenic purpura, severe aplastic anemia in patients with insufficient response to immunosuppressive therapy
- CLASS: Thrombopoietin receptor (TPO) agonist
- HALF-LIFE: 21–32 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antacids, Atorvastatin, Dairy products, Eluxadoline, Lopinavir, Mineral supplements, Olmesartan, Rosuvastatin, Selenium, Zinc
PREGNANCY CATEGORY: C
RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric